Non-Current Assets
Thermo Fisher Scientific·Balance Sheet Statement·10 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $98.5B | $100.4B | $97.3B | $99B | $101.2B | $103B | $110.3B | $113.3B |
| Goodwill | $43.8B | $46.7B | $45.9B | $46.5B | $47.2B | $49.3B | $49.4B | $55.2B |
| Other intangible assets—net | $15.5B | $16.3B | $15.5B | $15.3B | $15.1B | $16.2B | $15.8B | $19.1B |
| Property and equipment, net | $9.3B | $9.4B | $9.3B | $9.3B | $9.6B | $10.2B | $10.6B | $10.7B |
| Deferred Tax Assets and Other Non-Current Assets | $4.4B | $4.2B | $4.5B | $4.5B | $4.6B | $5B | $5.9B | $6B |
| Other non-current assets | $4.4B | $4.2B | $4.5B | $4.5B | $4.6B | $5B | $5.9B | $6B |
| Software and Technology Licenses, Net | $4.4B | $4.2B | $4.5B | $4.5B | $4.6B | $5B | $5.9B | $6B |
| Deferred tax assets | $1.5B | $1.1B | $1.3B | $1B | $624M | $842M | $1.5B | -$258M |
| Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) | $1.8B | $2B | $1.6B | $1.8B | $1.8B | $1.6B | $253M | $2M |
| Contract Assets, Non-Current | $7M | $8M | $6M | $4M | $1M | $1M | $1M | $1M |